


## AMENDMENT TO THE CLAIMS:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

## LISTING OF CLAIMS:

Claim 1. (Original) A compound of the formula



wherein R<sup>1</sup> is fluoro;

s is an integer from two to three;

R<sup>2</sup> is (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>4</sub>)alkyl, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, and (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-;

or R<sup>2</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-;

with the proviso that said compound of formula I cannot be

6-[4-(2,4-difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; or


6-[4-(3,4-difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine;

or a pharmaceutically acceptable salt thereof.


Claim 2. (Original) A compound according to claim 1 wherein R<sup>2</sup> is optionally substituted (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl.

Claim 3. (Original) A compound according to claim 2 wherein  $R^2$  is optionally substituted cyclopropyl, or cyclobutyl.


Claim 4. (Original) A compound according to claim 3, wherein the compound has the formula



Claim 5. (Original) A compound according to claim 3, wherein the compound has the formula



Claim 6. (Original) A compound according to claim 3, wherein the compound has the formula



Claim 7. (Original) A compound according to claim 3, wherein R<sup>2</sup> is (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl.

Claim 8. (Original) A compound according to claim 2, wherein R<sup>2</sup> is (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl substituted with one or two (C<sub>1</sub>-C<sub>3</sub>)alkyl.

Claim 9. (Original) A compound according to claim 2, wherein R<sup>2</sup> is (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl substituted with one or two methyl groups.

Claim 10. (Original) A compound according to claim 2, wherein R<sup>2</sup> is (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl substituted with one (C<sub>1</sub>-C<sub>3</sub>)alkyl.

Claim 11. (Original) A compound according to claim 2, wherein R<sup>2</sup> is (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl substituted with one methyl, ethyl or propyl group.

Claim 12. (Original) A compound according to claim 1, wherein said compound is selected from the group consisting of:

3-Cyclobutyl-6-[4-(2,5-difluoro-phenyl)-oxa- zol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine;  
6-[4-(2,4-Difluoro-phenyl)-oxazo- l-5-yl]-3-(1-methyl-cyclopropyl)-[1,2,4]triazolo[4,3-a]pyridine;

6-[4-(2,5-Difluoro-phenyl)-oxazol-5-yl]-3-(1-methyl-cyclopropyl)-[1,2,4]triazolo[4,3-a]pyridine;

3-Cyclopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine;  
and

3-Cyclopropyl-6-[4-(2,4-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine.

Claim 13. (Original) A compound according to claim 2, wherein said compound is selected from the group consisting of:

3-Cyclopropyl-6-[4-(2,4,5-trifluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine;  
and

3-(1-Methyl-cyclopropyl)-6-[4-(2,4,5-trifluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine.

Claim 14. (Original) A compound according to claim 1, wherein R<sup>2</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one or two groups independently selected from halo, hydroxy, and (C<sub>1</sub>-C<sub>6</sub>)alkoxy.

Claim 15. (Original) A compound according to claim 1, wherein R<sup>2</sup> is optionally substituted ethyl, isopropyl, isobutyl, t-butyl or sec-butyl.

Claim 16. (Original) A compound according to claim 14, wherein the compound has the formula 59.

Claim 17. (Original) A compound according to claim 14, wherein the compound has the formula 60.

Claim 18. (Original) A compound according to claim 14, wherein the compound has the formula 61.

Claim 19. (Original) A compound according to claim 14, wherein R<sup>2</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted with halo or hydroxy.

Claim 20. (Original) A compound according to claim 14, wherein R<sup>2</sup> is ethyl, isopropyl, isobutyl, t-butyl or sec-butyl; optionally substituted with a halo or hydroxy.

Claim 21. (Original) A compound according to claim 14, wherein R<sup>2</sup> is (C<sub>1</sub>-C<sub>4</sub>)alkyl.

Claim 22. (Original) A compound according to claim 14, wherein said compound is 3-tert-butyl-6-[4-(2,4-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-- a]pyridine.

Claim 23. (Original) A compound according to claim 14, wherein said compound is 6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a- ]pyridine.

Claim 24. (Original) A compound according to claim 14, wherein said compound is 3-tert-butyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-- a]pyridine.

Claim 25. (Original) A compound according to claim 14, wherein said compound is 3-tert-butyl-6-[4-(2,4,5-trifluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4- ,3-a]pyridine.

Claim 26. (Original) A compound according to claim 14, wherein said compound is 3-isopropyl-6-[4-(2,4,5-trifluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,- 3-a]pyridine.

Claim 27. (Original) A compound according to claim 14, wherein said compound is selected from the group consisting of:

3-Isopropyl-6-[4-(2,3,4-trifluoro-phenyl)-o- xazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine;

3-Isopropyl-6-[4-(2,3,5-triflu- oro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine;

3-Isopropyl-6-[4-(2,4,6-trifluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,- 3-a]pyridine;

and

3-Isopropyl-6-[4-(3,4,5-trifluoro-phenyl)-oxazol-5-yl]-[ - 1,2,4]triazolo[4,3-a]pyridine.

Claims 28-29. (Cancelled)

Claim 30. (Currently Amended) A method of treating a ~~condition selected from the disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis~~ shock arthritis in a mammal, ~~including a human~~, comprising administering to said mammal an amount of a compound according to claim 1 effective in treating such a condition.

Claim 31. (Currently Amended) A pharmaceutical composition ~~for the treatment of a condition selected from the group consisting of arthritis, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis~~ shock in a mammal, ~~including a human~~, comprising an amount of a compound of claim 1 effective in such treatment and a pharmaceutically acceptable carrier.

Claims 32-33. (Cancelled)